Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 1999

K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan.

This study was designed to evaluate the clinical significance of the use of preoperative serum tumor markers in primary epithelial ovarian cancer. Subjects comprised 111 patients with primary epithelial ovarian cancer. Lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), carcinoembryonic antigen (CEA), CA19-9, tissue polypeptide antigen (TPA), CA125 and sialyl TN (STN) serum levels were measured within 7 days before surgery. The tumor marker values were compared with the histopathologic diagnosis. The overall agreement between the test results and the actual outcome was calculated using Student's t test and analysis of variance (ANOVA). Survival curves were constructed according to the Kaplan-Meier method, and differences in survival were assessed with the log-rank test. The prognostic significance of tumor markers for survival was assessed in a multivariate analysis with the Cox proportional hazards model. Of the tumor markers examined in this study, CA125 showed the highest positive rate (77.6%), followed by 63.2% for STN and 55.9% for CA19-9. When the positive rate was compared according to histologic types, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma showed the highest positive rates for CA125 (94.1%), CA19-9 (76.9%), CA125 (91.7%) and STN (75.0%), respectively. Regarding the distribution of tumor marker levels according to the FIGO stage, LDH, HBDH, TPA and CA125 were correlated with the clinical stage while CEA, CA19-9 and STN did not show any correlation. From analyses of tumor marker levels according to histologic types, all patients with a ratio of CA125 to CEA of >1, 000 had serous cystadenocarcinoma and a ratio of CA125 to CA19-9 of >50 showed serous cystadenocarcinoma or endometrioid adenocarcinoma. On the other hand, all patients with a ratio of LDH or HBDH to CA19-9 of <1.0 had mucinous cystadenocarcinoma or clear cell carcinoma. From univariate analysis, the survival time of patients with elevated CA125, TPA or STN was significantly shorter than that of patients with normal CA125, TPA or STN levels. When the Cox's proportional hazard model was used, we identified age, clinical stage, clear cell carcinoma and serum STN as independent prognostic factors. Serum CA125, TPA or STN may give significant prognostic information in epithelial ovarian carcinoma. It is noteworthy that STN has been identified as an independent prognostic factor and has a high rate of positivity in clear cell carcinoma.

UI MeSH Term Description Entries
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006884 Hydroxybutyrate Dehydrogenase 3-Hydroxybutyrate Dehydrogenase,D-3-Hydroxybutyrate Dehydrogenase,D-beta-Hydroxybutyrate Dehydrogenase,3 Hydroxybutyrate Dehydrogenase,D 3 Hydroxybutyrate Dehydrogenase,D beta Hydroxybutyrate Dehydrogenase,Dehydrogenase, 3-Hydroxybutyrate,Dehydrogenase, D-3-Hydroxybutyrate,Dehydrogenase, D-beta-Hydroxybutyrate,Dehydrogenase, Hydroxybutyrate
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
February 2009, Zhonghua fu chan ke za zhi,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
February 2012, Chinese medical journal,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
March 1986, Obstetrics and gynecology,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
January 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
March 2011, Immunobiology,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
May 2000, Gynecologic oncology,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
January 1982, Voprosy onkologii,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
May 2000, Nihon rinsho. Japanese journal of clinical medicine,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
January 1999, Anticancer research,
K Kudoh, and Y Kikuchi, and T Kita, and T Tode, and M Takano, and J Hirata, and Y Mano, and K Yamamoto, and I Nagata
October 1989, Tumori,
Copied contents to your clipboard!